Treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in six ODYSSEY phase 3 clinical studies with treatment duration of 52 – 104 weeks

Abstract

Peer reviewed

M. Farnier, H.M. Colhoun, W.J. Sasiela, J. Edelberg, G. Asset and J.G. Robinson

Atherosclerosis, Vol.252, pp.e254-e254

09/2016

DOI: 10.1016/j.atherosclerosis.2016.07.070

View Online

Title: Subtitle: Treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in six ODYSSEY phase 3 clinical studies with treatment duration of 52 – 104 weeks
Creators: M. Farnier - Point Medical, Dijon, France
H.M. Colhoun - University of Dundee
W.J. Sasiela - Regeneron
J. Edelberg - Sanofi, Head of PCSK9 Development Launch Unit, Bridgewater, USA
G. Asset - Sanofi
J.G. Robinson - University of Iowa
Resource Type: Abstract
Publication Details: Atherosclerosis, Vol.252, pp.e254-e254
Publisher: Elsevier B.V
DOI: 10.1016/j.atherosclerosis.2016.07.070
ISSN: 0021-9150
eISSN: 1879-1484
Language: English
Date published: 09/2016
Academic Unit: Epidemiology; Fraternal Order of Eagles Diabetes Research Center
Record Identifier: 9984364533302771

1 Record Views